vs

Side-by-side financial comparison of FRANKLIN FINANCIAL SERVICES CORP (FRAF) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $23.3M, roughly 1.5× FRANKLIN FINANCIAL SERVICES CORP). FRANKLIN FINANCIAL SERVICES CORP runs the higher net margin — 25.9% vs -304.2%, a 330.2% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 51.5%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 14.6%).

Franklin Financial Services Corp (Pennsylvania) is a U.S. regional bank holding company primarily operating across Pennsylvania. It provides comprehensive retail and commercial banking services, including deposit products, personal and business loans, mortgage financing, and wealth management solutions for individual consumers, small local businesses and regional institutional clients.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FRAF vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.5× larger
RXRX
$35.5M
$23.3M
FRAF
Growing faster (revenue YoY)
RXRX
RXRX
+630.2% gap
RXRX
681.7%
51.5%
FRAF
Higher net margin
FRAF
FRAF
330.2% more per $
FRAF
25.9%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
14.6%
FRAF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FRAF
FRAF
RXRX
RXRX
Revenue
$23.3M
$35.5M
Net Profit
$6.0M
$-108.1M
Gross Margin
59.8%
Operating Margin
32.1%
-304.8%
Net Margin
25.9%
-304.2%
Revenue YoY
51.5%
681.7%
Net Profit YoY
1140.7%
39.6%
EPS (diluted)
$1.35
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRAF
FRAF
RXRX
RXRX
Q4 25
$23.3M
$35.5M
Q3 25
$23.0M
$5.2M
Q2 25
$22.3M
$19.2M
Q1 25
$20.2M
$14.7M
Q4 24
$15.4M
$4.5M
Q3 24
$19.5M
$26.1M
Q2 24
$18.6M
$14.4M
Q1 24
$17.7M
$13.8M
Net Profit
FRAF
FRAF
RXRX
RXRX
Q4 25
$6.0M
$-108.1M
Q3 25
$5.4M
$-162.3M
Q2 25
$5.9M
$-171.9M
Q1 25
$3.9M
$-202.5M
Q4 24
$487.0K
$-178.9M
Q3 24
$4.2M
$-95.8M
Q2 24
$3.0M
$-97.5M
Q1 24
$3.4M
$-91.4M
Gross Margin
FRAF
FRAF
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
FRAF
FRAF
RXRX
RXRX
Q4 25
32.1%
-304.8%
Q3 25
28.9%
-3327.6%
Q2 25
32.8%
-916.8%
Q1 25
23.9%
-1297.9%
Q4 24
3.4%
-4042.4%
Q3 24
26.2%
-377.1%
Q2 24
19.8%
-697.4%
Q1 24
22.6%
-698.4%
Net Margin
FRAF
FRAF
RXRX
RXRX
Q4 25
25.9%
-304.2%
Q3 25
23.3%
-3135.3%
Q2 25
26.4%
-894.2%
Q1 25
19.4%
-1373.3%
Q4 24
3.2%
-3935.5%
Q3 24
21.6%
-367.5%
Q2 24
16.3%
-676.6%
Q1 24
18.9%
-662.4%
EPS (diluted)
FRAF
FRAF
RXRX
RXRX
Q4 25
$1.35
$-0.17
Q3 25
$1.19
$-0.36
Q2 25
$1.32
$-0.41
Q1 25
$0.88
$-0.50
Q4 24
$0.13
$-0.56
Q3 24
$0.95
$-0.34
Q2 24
$0.66
$-0.40
Q1 24
$0.77
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRAF
FRAF
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$127.7M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$175.2M
$1.1B
Total Assets
$2.2B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRAF
FRAF
RXRX
RXRX
Q4 25
$127.7M
$743.3M
Q3 25
$188.1M
$659.8M
Q2 25
$207.8M
$525.1M
Q1 25
$225.0M
$500.5M
Q4 24
$203.6M
$594.4M
Q3 24
$236.3M
$427.6M
Q2 24
$179.7M
$474.3M
Q1 24
$182.6M
$296.3M
Total Debt
FRAF
FRAF
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
FRAF
FRAF
RXRX
RXRX
Q4 25
$175.2M
$1.1B
Q3 25
$166.3M
$1.0B
Q2 25
$157.4M
$919.1M
Q1 25
$151.4M
$933.9M
Q4 24
$144.7M
$1.0B
Q3 24
$149.9M
$524.6M
Q2 24
$136.8M
$584.4M
Q1 24
$134.2M
$401.2M
Total Assets
FRAF
FRAF
RXRX
RXRX
Q4 25
$2.2B
$1.5B
Q3 25
$2.3B
$1.4B
Q2 25
$2.3B
$1.3B
Q1 25
$2.3B
$1.3B
Q4 24
$2.2B
$1.4B
Q3 24
$2.2B
$726.5M
Q2 24
$2.0B
$775.9M
Q1 24
$2.0B
$557.8M
Debt / Equity
FRAF
FRAF
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRAF
FRAF
RXRX
RXRX
Operating Cash FlowLast quarter
$25.4M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
4.21×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRAF
FRAF
RXRX
RXRX
Q4 25
$25.4M
$-46.1M
Q3 25
$8.3M
$-117.4M
Q2 25
$5.1M
$-76.4M
Q1 25
$8.8M
$-132.0M
Q4 24
$21.8M
$-115.4M
Q3 24
$7.8M
$-59.2M
Q2 24
$2.4M
$-82.2M
Q1 24
$7.3M
$-102.3M
Free Cash Flow
FRAF
FRAF
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
FRAF
FRAF
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
FRAF
FRAF
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
FRAF
FRAF
RXRX
RXRX
Q4 25
4.21×
Q3 25
1.55×
Q2 25
0.87×
Q1 25
2.25×
Q4 24
44.67×
Q3 24
1.85×
Q2 24
0.80×
Q1 24
2.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons